Prana Biotechnology announced that Dr. Rudy Tanzi, Scientific Advisory Board will present at the 2009 Windhover’s Therapeutic Area Partnerships Conference being held November 18 at 3:30PM at the Westin Copley Place Hotel in Boston.

Prana’s lead Alzheimer’s disease compound, PBT2, has been chosen by Windhover Information and independent expert Harry Tracy, as one of the top 10 most interesting neuroscience projects in development available for strategic partnering.

Last Trade: 1.31
Trade Time: Dec 24
Prev Close: 1.3112
Open: N/A
Day’s Range: N/A – N/A
52wk Range: 1.00 – 3.11
Volume: 0
Avg Vol (3m): 14,338.5
Market Cap: N/A

About Prana Biotechnology Ltd.

Prana Biotechnology Limited (Prana) is a development-stage company at an early stage in the development of its pharmaceutical products that are designed to treat the underlying causes of degeneration of the brain and the eye as the aging process progresses. Other potential applications for the Company’s therapies include Huntington’s disease, Parkinson’s disease, certain cancers, age-related macular degeneration, Motor Neuron disease, Creutzfeldt-Jakob disease (the human variant of Mad Cow disease) and age-related cataracts. The Company has two wholly owned subsidiaries, Prana Biotechnology Inc. and Prana Biotechnology UK Limited. Prana’s activities are focused within Australia and cover research into Alzheimer’s disease and other age-related degenerative disorders.